BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences
November 12 2021 - 9:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
(TSX-V:BCT) (“BriaCell” or the “Company”), a
clinical-stage biotechnology company specializing in targeted
immunotherapies for advanced breast cancer and other cancers, today
announces the following updates:
Pursuant to the securities buyback program
announced Sept. 9, 2021, BriaCell has repurchased 202,425 common
shares (the “Common Shares”) and 70,246 publicly traded BCTXW
warrants (the “Listed Warrants”). As announced, BriaCell may
purchase through the facilities of the TSX Venture Exchange
("TSXV") or the Nasdaq Capital Market ("Nasdaq") or alternative
exchanges (i) up to 1,341,515 Common Shares and (ii) up to 411,962
publicly traded BCTXW Listed Warrants in total, representing 10% of
the 13,415,154 Common Shares and 10% of the 4,119,622 Listed
Warrants comprising the "public float" as of September 8, 2021,
over the next 12 months.
BriaCell is fully-capitalized to achieve its
strategic clinical milestones. Because of this BriaCell’s Board of
Directors believes the best use of a portion of its excess capital
at this time is to buy back its own Common Shares and Listed
Warrants for cancellation. As of July 31, 2021, BriaCell’s cash
balance was US$57.3 million which provides the strength and
flexibility to execute both the buyback program and BriaCell’s
growth strategy to expand into previously-announced areas of cancer
immunotherapy and/or advance its current breast cancer clinical
trials.
Separately, the Company announces that Dr.
William V. Williams, President & CEO of BriaCell, is scheduled
to present at the following virtual conferences:
- Q4 Investor Summit: November 16 – 17, 2021
- Dr. Williams will deliver his corporate presentation at 10:15
a.m. ET on November 16, 2021
- Investors may register for the conference at:
https://investorsummitgroup.com/
- Investors may request one-on-one meetings with management
- A public webcast can be accessed via the following
link: https://us06web.zoom.us/webinar/register/WN_qK33aeh9TOmLiCnC-GM91w
- The 2021 San Antonio Breast Cancer Symposium®: December
7 – 10, 2021
- BriaCell’s lead product candidate, Bria-IMT™, will be featured
during the following:
- Poster Session 2: 5:00 - 6:30 p.m. CT on
Wednesday, December 8, 2021
- Presentation Title: Overall Survival Following
Treatment with a Modified Whole Tumor Cell Targeted Immunotherapy
in Patients with Advanced Breast Cancer
- The poster presentation will be accessible at a later date
at: https://briacell.com/novel-technology/scientific-publications/
- MedInvest Oncology Conference: December 7 – 10,
2021
- Dr. Williams will be speaking at the conference at 2:30 p.m. ET
on December 7, 2021
- Investors may register for the conference at:
https://www.medinvestconferences.com/
- Investors may request on-on-one meetings with management
- Benzinga Global Small Cap Virtual Investor
Conference: December 8 – 9, 2021
- Dr. Williams will be speaking at the conference at 1:35 p.m. ET
on December 9, 2021
- Investors may register for the conference
at: https://www.benzinga.com/events/small-cap/december-2021-global/
- Investors may request on-on-one meetings with management
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading "Risks and Uncertainties" in the
Company's most recent Management’s Discussion and Analysis, under
“Risks and Uncertainties” in the Company's other filings with the
Canadian securities regulatory authorities and the U.S. Securities
and Exchange Commission, all of which are available under our
profiles on SEDAR at www.sedar.com and on EDGAR at
www.sec.gov. Forward-looking statements contained
in this announcement are made as of this date, and BriaCell
Therapeutics Corp. undertakes no duty to update such information
except as required under applicable law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
Company Contact: William V.
Williams, MD President & CEO 1-888-485-6340
info@briacell.com
Media Relations: Jules Abraham
Director of Public Relations CORE IR 917-885-7378
julesa@coreir.com
Investor Relations Contact: CORE
IR investors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2023 to Aug 2024